VANCOUVER, August 18, 2016, — Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), (“Veritas” or the “Company”), is pleased to announce that it will be attending three important events next month –the European Respiratory Society International Congress in London, UK as well as the Lift’s Canadian Cannabis Business conference and Cannabis Expo in Vancouver, Canada.  These meetings will inform the Company about the current state of cannabis research from different parts of the world, along with further insight about the legalization and public health & safety concerns of medicinal cannabis from a Canadian perspective.

From September 3-7, the European Respiratory Society will have posters and related discussions about the health outcomes, socioeconomic impact, and the respiratory effects of cannabis use.  More information can be found at

From September 12-16, The Canadian Cannabis Business Conference will examine the different aspects of the emerging medical and recreational cannabis industry in Canada.  The range of topics include: law and regulations, public health and safety, finance and banking, public and government relations, as well as marketing and advertising.  (Lift is a Canadian online information portal and meeting organizer that aims to ‘facilitate conversations and spread credible information in an era of rapid legitimization and growth of the new cannabis economy’).  More information about this event can be found at

From September 17-18, the Lift Cannabis Expo will have over 100 businesses from around the world showcasing their best cannabis products and services for consumers.  More information about this event can be found at

As well, Cannevert Therapeutics Ltd, which is Veritas’ exclusive partner and high-level R&D arm, is currently preparing its next quarterly research report.  The Company expects to receive it toward the end of Q3 or early Q4 this year.

About Veritas Pharma Inc. 

Veritas Pharma Inc. is an emerging discovery and IP development company, advancing the science behind medical cannabis. The company’s current R&D efforts are to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for real science to support medical marijuana claims.

Our unique value proposition employs a whole plant methodology, using a low cost research and development model to help drive shareholder value and speed-to-market. Veritas is led by strong management, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect its IP (cultivars/ strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.

Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.
For more information, please visit our website:

On behalf of the Board of Directors; Veritas Pharma Inc.
Dr. Lui Franciosi
Chief Executive Officer

Further information about the Company is available on our website at or under our profile on SEDAR at and on the CSE website at

Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: [email protected]

The CSE has not reviewed, nor approved or disapproved the content of this press release.

The Veritas Newsletter

Enter your email to receive news alerts and updates from Veritas Pharma.

You have Successfully Subscribed!